

headache, nausea, or vomiting was present, a physician should be consulted immediately.

DISPOSITION: 3-23-61. Default—destruction.

6558. Think-Eze tablets. (F.D.C. No. 45272. S. No. 17-684 R.)

QUANTITY: 73 100-tablet btls., 446 48-tablet btls., 394 24-tablet btls., and 287 8-tablet pkgs., at Denver, Colo.

SHIPPED: On 8-2-60 and dates subsequent thereto, from Huntington Park, Calif., by Retail Distributors Service, Inc.

LABEL IN PART: (Btl. and pkg.) "Think-Eze has a Tranquilizer action—An Aid To Relieve Nervous Tensions and help to obtain Normal Steady Nerves * * * Aldan Distributors, Inc., New York, N.Y. Long Beach, Calif. * * * Each Think-Eze tablet contains: Thiamine HCl (Vit. B-1) 1 mg. Niacinamide 5 mg. Ammonium and Sodium Bromides 4.75 gr. blended in a specially formulated and prepared inert base containing: Salicylamide, Glycyrrhiza Extract, Valerian Root, Pleurisy Root, Humulus Lupulus, Extract of Jamaica Dogwood."

ACCOMPANYING LABELING: Window banners reading in part "Think-Eze Tablets . . . With * * * Tranquilizer Action" and a number of large and small display units.

LIBELED: 12-7-60, Dist. Colo.

CHARGE: 502(a)—when shipped and while held for sale, the labeling of the article contained false and misleading representations that the article was adequate and effective as a treatment for nervous tensions, emotionally upset stomach, mental depression, and nerve-racking headaches; 502(a)—the statement "Tranquilizer" appearing on the labels and in the accompanying labeling when read in the setting in which presented, represented and suggested that the article would produce all of the effects capable of being produced by a commonly accepted true "tranquilizer" drug, whereas, the article was not a "tranquilizer" drug and would not produce all of the effects capable of being produced by a true "tranquilizer," and it would not provide the tranquilizing benefits claimed for it; 502(c)—the ingredient information required under 502(e) (2) and the warnings required by 502(f) (2) to appear in the labeling of the article were not prominently placed on the label and labeling with such conspicuousness, as compared with other statements on the label and labeling, as to render such information and warnings likely to be read and understood by the ordinary individual under customary conditions of purchase and sale; and 502(f) (2)—the labeling of the article failed to warn that it should not be given to children, and that its use should be discontinued if nervous symptoms persisted, recurred frequently, or were unusual.

DISPOSITION: 3-20-61. Default—destruction.

6559. Analjel. (F.D.C. No. 45189. S. No. 20-039 R.)

QUANTITY: 396 btls. at Lorain, Ohio.

SHIPPED: 8-16-60, from Pittsburgh, Pa., by the Federal Rice Drug Co.

LABEL IN PART: (Btl.) "Analjel a Nongreasy Analgesic Balm 2 Oz. Detroit First Aid Co., Detroit, Michigan Contents: Methyl Salicylate, Natural Menthol, Camphor, Oil of Peppermint."

LIBELED: 1-3-61, N. Dist. Ohio.

CHARGE: 502(a)—when shipped, the bottle label contained false and misleading representations that the article was an adequate and effective treatment